Point72 Asset Management L.P. purchased a new stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,400 shares of the medical instruments supplier’s stock, valued at approximately $122,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in OraSure Technologies during the first quarter valued at about $113,000. Cubist Systematic Strategies LLC bought a new position in shares of OraSure Technologies during the first quarter valued at about $139,000. Private Advisor Group LLC bought a new position in shares of OraSure Technologies during the first quarter valued at about $181,000. Engineers Gate Manager LP bought a new position in shares of OraSure Technologies during the second quarter valued at about $197,000. Finally, Xact Kapitalforvaltning AB bought a new position in shares of OraSure Technologies during the second quarter valued at about $198,000. Institutional investors and hedge funds own 91.76% of the company’s stock.
In related news, Director Charles W. Patrick sold 8,000 shares of the stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $16.29, for a total value of $130,320.00. Following the completion of the transaction, the director now directly owns 54,298 shares of the company’s stock, valued at $884,514.42. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 2.90% of the stock is owned by corporate insiders.
Shares of NASDAQ:OSUR opened at $15.25 on Tuesday. OraSure Technologies, Inc. has a 12 month low of $12.86 and a 12 month high of $23.01. The stock has a market cap of $937.79 million, a PE ratio of 29.90, a PEG ratio of 3.41 and a beta of 1.61.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, August 8th. The medical instruments supplier reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.03. OraSure Technologies had a net margin of 8.38% and a return on equity of 5.85%. The company had revenue of $43.60 million during the quarter, compared to the consensus estimate of $42.24 million. During the same period in the prior year, the firm earned $0.09 earnings per share. OraSure Technologies’s revenue was up 8.5% on a year-over-year basis. sell-side analysts predict that OraSure Technologies, Inc. will post 0.36 EPS for the current year.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Read More: Stock Symbols Definition, Examples, Lookup
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.